GlobalGov › Germany › Pharmaceuticals › Solicitation

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-20 - Pegfilgrastim

Health, Health, Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

August 30, 2027
Response Due
Active
Status

Opportunity Overview

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-20 - Pegfilgrastim is a active solicitation for government procurement in Germany, issued by Health, Health, Health and tracked by GlobalGov. It falls under Pharmaceuticals. Responses are due by August 30, 2027. It was published on July 17, 2025. Full solicitation details, all dates, and related live opportunities are below.

This is one of 1,400 active Germany Pharmaceuticals opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHealth, Health, Health
CountryGermany
CategoryPharmaceuticals
PublishedJuly 17, 2025
Procurement stageActive solicitation
Response dueAugust 30, 2027
StatusOpen — accepting responses
TranslationTranslated from Swedish by GlobalGov’s translation pipeline
Official sourceView original notice
Last verifiedAugust 09, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Germany market overview →Pharmaceuticals tenders in Germany →Browse all categories →

Related Opportunities in Germany

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Distigmin (ATC-Code nach WHO: N07AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarung nach § 130a Abs. 8 SGB V zu dem Wirkstoff Ciclosporin (S01XA18)
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Tamoxifen, ATC L02BA01
Germany – Pharmaceutical products – Open-House-Verträge 2025-5 - Aflibercept
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Colestyramin (C10AC01).
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Naloxegol (ATC-Code nach WHO: A06AH03)
Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Tafluprost (ATC: S01EE05)
Germany – Pharmaceutical products – Open house drug discount contracts Eltrombopag, ATC B02BX05

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.